Avenue Therapeutics, Inc. (ATXI) Key Metrics
ATXI valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $1.3M
- Enterprise value
- −$755,812
- P/E (TTM)
- —
- Forward P/E
- 18.0
- PEG ratio
- —
- Price / sales
- 0.7
- Price / book
- 2.1 10-yr median 9.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.23
ATXI key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsATXI valuation Price multiples at each fiscal year-end price.
ATXI returns How much profit the business earns on the capital it uses.
ATXI per-share figures Results divided by the shares outstanding at year-end.
ATXI financial health Debt, liquidity and how easily interest is covered.
ATXI valuation history
ATXI returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ATXI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ATXI cash returned to shareholders
ATXI price vs earnings per share
ATXI key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $2.1M | $25.9M | — | — | $1.16B | $7.36B | $11.32B | $4.15B | — | — |
| Enterprise value | −$725,205 | $23.3M | — | — | $1.15B | $7.36B | $11.31B | $4.14B | — | — |
| Price / sales | 1.5 | — | — | — | — | — | — | — | — | — |
| Price / book | 1.2 | 9.3 | — | — | 335.4 | — | — | — | — | — |
| EV / sales | -0.5 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −136.6% | −45.0% | — | — | −0.3% | −0.1% | −0.2% | −0.5% | — | — |
| Free cash flow yield | −86.1% | −34.8% | — | — | −0.3% | −0.1% | −0.2% | −0.4% | — | — |
| Shareholder yield (dividends + buybacks) | 0.2% | — | — | — | 0.0% | — | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $0.68 | $2.00 | $12.07 | $87.00 | $1,021.50 | $6,693.75 | $10,800.00 | $6,075.00 | $4,072.50 | — |
| Per share | ||||||||||
| Revenue per share | $0.45 | $0.00 | — | — | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Earnings per share | −$0.93 | −$0.90 | — | — | −$3.29 | −$4.63 | −$24.38 | −$31.57 | — | — |
| Operating cash flow per share | −$0.59 | −$0.70 | — | — | −$3.31 | −$4.19 | −$25.06 | −$26.69 | — | — |
| Free cash flow per share | −$0.59 | −$0.70 | — | — | −$3.31 | −$5.10 | −$25.06 | −$26.69 | — | — |
| Cash per share | $0.91 | $0.20 | — | — | $3.32 | $2.85 | $8.34 | $3.91 | — | — |
| Book value per share | $0.59 | $0.22 | — | — | $3.05 | $2.14 | $6.49 | −$0.92 | — | — |
| Tangible book value per share | $0.59 | $0.22 | — | — | $3.05 | $2.14 | $6.49 | −$0.92 | — | — |
| Capex per share | $0.00 | $0.00 | — | — | $0.00 | $0.91 | $0.00 | $0.00 | — | — |
| Shares outstanding | 3.1M | 13.0M | — | — | 1.1M | 1.1M | 1.0M | 683K | — | — |
| Change in shares outstanding | −75.8% | — | — | — | +3.0% | +5.0% | +53.5% | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −125.7% | −532.2% | −378.2% | −96.6% | −128.2% | −111.1% | −828.4% | — | −220.2% | — |
| Return on assets (ROA) | −103.8% | −515.3% | −238.7% | −65.7% | −103.4% | −83.7% | −380.2% | −161.4% | −109.6% | — |
| Return on tangible assets | −99.2% | −436.1% | −560.9% | −51.9% | −94.0% | −156.8% | −286.6% | −476.2% | −55.3% | — |
| Free cash flow margin | −130.6% | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | — | — | — | — | — | — | — | — | $0 | $5.9M |
| Cash & short-term investments | $2.9M | $2.6M | $1.8M | $6.7M | $3.8M | $3.1M | $8.7M | $2.7M | $21.8M | $197,000 |
| Net debt | −$2.9M | −$2.6M | −$1.8M | −$6.7M | −$3.8M | −$3.1M | −$8.7M | −$2.7M | −$21.8M | $5.7M |
| Debt / equity | — | — | — | — | — | — | — | — | 0.00 | — |
| Debt / assets | — | — | — | — | — | — | — | — | 0.00 | 29.82 |
| Net debt / EBITDA | — | — | −0.44 | — | — | — | — | −9.97 | — | — |
| Current ratio | 2.60 | 3.27 | 1.55 | 1.91 | 7.78 | 3.66 | 4.22 | 0.88 | 7.95 | 0.03 |
| Quick ratio | 2.60 | 3.27 | 1.55 | 1.91 | 7.57 | 3.66 | 4.22 | 0.88 | 7.95 | 0.03 |
| Interest coverage | — | — | -43.8 | -6.9 | -534.0 | — | — | — | -30.5 | -3.9 |
| Working capital | $1.8M | $1.9M | $654,000 | $3.3M | $3.5M | $2.4M | $6.8M | −$631,000 | $19.4M | −$6.2M |
| Invested capital | −$1.0M | $203,000 | −$201,000 | −$2.8M | −$312,000 | −$773,000 | −$1.9M | −$3.3M | −$2.4M | −$2.6M |
| Tangible asset value | $1.8M | $1.9M | $654,000 | $3.3M | $3.5M | $2.4M | $6.8M | −$631,000 | $19.4M | −$8.2M |
| Net current asset value | $1.8M | $1.9M | $654,000 | $3.3M | $3.5M | $2.4M | $6.8M | −$631,000 | $19.4M | −$8.2M |
| Graham net-net per share | $0.56 | $0.14 | — | — | $2.98 | $2.04 | $6.33 | −$3.64 | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | — |
| Share buybacks (net) | $4,000 | — | $0 | $1.1M | $0 | — | $0 | $895,000 | $0 | $0 |
| Capex / revenue | 0.0% | — | — | — | — | — | — | — | — | — |
| Capex / depreciation | — | — | 0.21 | 0.00 | 0.00 | 191.83 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | 47.4% | — | — | — | — | — | — | — | — | — |
| R&D / revenue | 73.9% | — | — | — | — | — | — | — | — | — |
| SG&A / revenue | 260.2% | — | — | — | — | — | — | — | — | — |
| Efficiency | ||||||||||
| Receivables turnover | — | — | — | — | 0.00 | — | — | — | — | — |
| Payables turnover | 0.00 | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Asset turnover | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | — | $90,000 | — | — | — | — | — |
| Average payables | $124,500 | $278,000 | $275,500 | $227,000 | $238,000 | $263,000 | $1.7M | $2.3M | $939,500 | $412,500 |
| Average inventory | — | — | — | — | $106,803 | — | — | — | $0 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ATXI's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ATXI valuation and financial ratios
Avenue Therapeutics earned a return on equity of −125.7% in fiscal 2025. It returned $0.0 million to shareholders: $0 in dividends and $0.0 million in share buybacks.
See the ATXI income statement, the ATXI chart for price history, or the ATXI stock overview for the latest quote and news.
ATXI key metrics FAQ
What is Avenue Therapeutics's return on equity?
Avenue Therapeutics's return on equity (ROE) was −125.7% in fiscal 2025: net income of -$2.9 million on average shareholders' equity of $2.3 million.
Does Avenue Therapeutics buy back its shares?
Yes. Avenue Therapeutics spent $0.0 million on net share repurchases in fiscal 2025 Shares outstanding changed −75.8% over the year, to 3.1M..
What is Avenue Therapeutics's free cash flow yield?
Avenue Therapeutics generated -$1.8 million of free cash flow in fiscal 2025, a free cash flow yield of −86.1% on its market value at year-end ($2.1 million).
What is Avenue Therapeutics's current ratio?
Avenue Therapeutics's current ratio was 2.60 at the end of fiscal 2025: current assets were 2.60 times current liabilities.